EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis

Chenxi Zeng iD, Huihui Yue, Congjian Wang, Xuetao Ju, Tianlai Wang, Xiangning Fu, Qing Zhou, Huilan Zhang, Long He, Jun Yu, Yi Wang

Journal of Translational Medicine · 07.10.2024 · 22 (1)

DOI: 10.1186/s12967-024-05655-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Medicine, online erschienen am 07.10.2024. Verfasst von Chenxi Zeng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 4300…. Hauptthemen laut MEDLINE: Albendazole, Myofibroblasts, Glycolysis, Transforming Growth Factor beta1. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and lethal lung disorder for which effective treatments remain limited. Recent investigations revealed a potential link between altered glucose metabolism and the activation of fibroblasts, the key cells responsible for generating and depositing extracellular matrix proteins within the lung interstitium during IPF development. METHOD: In this study, we aimed to investigate the potential therapeutic impact of albendazole on fibroblast to myofibroblast transition in IPF. We assess albendazole's effectiveness in attenuating the activation of fibroblasts. We focused on elucidating the mechanism underlying albendazole's impact on TGF-β1-induced aerobic glycolysis in both lung tissues and fibroblasts obtained from patients with IPF and other lung fibrosis types. Furthermore, the antifibrotic effects of oral administration of albendazole were investigated in mouse models of pulmonary fibrosis induced by BLM or SiO2. Human precision-cut lung slices were employed to evaluate the impact of albendazole following TGF-β1 stimulation. RESULT: In this work, we demonstrated that albendazole, a first-line broad-spectrum anthelmintic drug, effectively attenuated fibroblast to myofibroblast transition through alleviating TGF-β1-induced aerobic glycolysis dependent on the LRRN3/PFKFB3 signaling pathway. Additionally, LRRN3 expression was downregulated in both lung tissues and fibroblasts from patients with IPF and other types of lung fibrosis. Importantly, the levels of LRRN3 correlated with the progression of the disease. Notably, oral administration of albendazole exerted potent antifibrotic effects in mouse models of pulmonary fibrosis induced by BLM or SiO2, and in human precision-cut lung slices after TGF-β1 stimulation, as evidenced by improvements in lung morphology, reduced myofibroblast formation, and downregulation of α-SMA, collagen type 1 and Fibronectin expression in the lungs. CONCLUSION: Our study implies that albendazole can act as a potent agonist of LRRN3 during fibroblast to myofibroblast differentiation and its oral administration shows potential as a viable therapeutic approach for managing IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleMyofibroblastsGlycolysisTransforming Growth Factor beta1Pulmonary FibrosisAnimalsHumansMice, Inbred C57BLLungMaleMiceSignal TransductionDisease Models, AnimalBleomycinFemale

Stichwörter der Autor:innen

Aerobic glycolysisAlbendazoleFibroblastIdiopathic pulmonary fibrosisMyofibroblast

Substanzen

AlbendazoleTransforming Growth Factor beta1Bleomycin

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.
  • Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious…
  • Department of Clinical Laboratory, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China. helong@tongji.edu.cn.
  • Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China. junyu2018@hotmail.com.

ORCID-Profile: Chenxi Zeng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zeng, C., Yue, H., Wang, C., Ju, X., Wang, T., Fu, X., Zhou, Q., Zhang, H., He, L., Yu, J., & Wang, Y. (2024). Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05655-0

Vancouver

Zeng C, Yue H, Wang C, Ju X, Wang T, Fu X, et al. Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis. Journal of Translational Medicine. 2024;22(1). doi:10.1186/s12967-024-05655-0

BibTeX
@article{Zeng2024,
  author = {Zeng, Chenxi and Yue, Huihui and Wang, Congjian and Ju, Xuetao and Wang, Tianlai and Fu, Xiangning and Zhou, Qing and Zhang, Huilan and He, Long and Yu, Jun and Wang, Yi},
  title = {Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosis},
  journal = {Journal of Translational Medicine},
  year = {2024},
  volume = {22},
  number = {1},
  doi = {10.1186/s12967-024-05655-0}
}
Kostenlos starten →